Secondary Prophylaxis of Docetaxel Induced Diarrhea with Loperamide: Case Report

Hee Yeon Lee, Youn Hee Lee, Min Ji Kim, and Hoon-Kyo Kim

Division of Medical Oncology, Department of Internal Medicine, St. Vincent’s Hospital, The Catholic University of Korea, Suwon, Korea

Received: 15 January 2013
Accepted: 13 May 2013

Address for Correspondence:
Hoon-Kyo Kim, MD
Division of Medical Oncology, Department of Internal Medicine, St. Vincent’s Hospital, The Catholic University of Korea, 93 Jungbuk-daero, Paldal-gu, Suwon 442-723, Korea
Tel: +82.31-249-7177, Fax: +82.31-253-8898
E-mail: miongsok@catholic.ac.kr

Key Words: Docetaxel; Diarrhea; Loperamide

INTRODUCTION

Many chemotherapeutic agents including irinotecan, 5-fluorouracil, capecitabine, docetaxel, paclitaxel, doxorubicin, interferon, and gefitinib are commonly associated with diarrhea (1). The mechanism of chemotherapy induced diarrhea (CID) is not entirely understood but is believed to be primarily secretory, and may have an exudative component (2). Main aims of standard guidelines for CID are to reduce the volume of diarrhea, to treat dehydration aggressively, and to use antibiotics if needed (2, 3). And in pharmacological managements, loperamide plays a main role (1-4). But prophylaxis for CID is not well established.

Docetaxel is a semi-synthetic taxane, with considerable activity against several types of solid tumors including breast, ovarian, gastric, prostate and non-small-cell lung cancers. Docetaxel binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell cycle arrest at the G2/M phase and cell death (5). Frequent side effects of docetaxel include fluid retention, neurosensory events, alopecia, cutaneous events, stomatitis, nausea, vomiting, diarrhea, and neutropenia. Diarrhea develops in 20%-40% of patients with docetaxel-containing chemotherapy and severe diarrhea in 5%-6% (6).

In this report, we describe a new prophylactic approach for the docetaxel induced diarrhea with loperamide in a patient with non-small-cell lung cancer.

CASE DESCRIPTION

Diarrhea is a common adverse event of docetaxel with 20%-40% of incidence and severe diarrhea occurs in 5%-6%. Several treatment guidelines for chemotherapy induced diarrhea (CID) exist, however the prophylaxis for that is not well known. We describe a new prophylactic approach for the CID with loperamide. A 72-yr-old male patient with stage IV non-small-cell lung cancer developed diarrhea repeatedly after docetaxel-cisplatin chemotherapy. His diarrhea persisted despite treatment including loperamide and fasting. However, the diarrhea was successfully prevented when loperamide was given before and after the chemotherapy. To our knowledge, this is the first report of prophylactic approach for the CID with loperamide.
veloped again and he visited emergency room. The same management with loperamide was done for 3 days and diarrhea was resolved.

We concluded that docetaxel induced his diarrhea because of several reasons: no signs of infection, no use of antibiotics, repeated diarrhea after chemotherapy and little probability of diarrhea with other medications including dexamethasone, palonosetron and cisplatin. Chest computed tomography after 2 cycles of DP showed near complete response according to RECIST v 1.1 (Fig. 1). Thus we decided to continue DP chemotherapy despite of the severe repeated docetaxel induced diarrhea.

On day 1 of the 3rd DP chemotherapy with 20% reduced dose, prophylactic loperamide (2 mg every 8 hr) and fasting was started before administration of chemotherapy. Diarrhea did not develop with 4 days of fasting and 7 days of loperamide. Day 8 DP of 3rd cycle was delayed due to grade 2 asthenia and started on day 15. On day 15, prophylactic loperamide was started before chemotherapy and fasting was started after administration of chemotherapy. The duration of fasting and administration of loperamide were shortened to 2 and 5 days, respectively. The 3rd cycle was completed without diarrhea. Subsequent cycles of DP chemotherapy with 20% reduced dose could be given without diarrhea by virtue of loperamide. Now he finished 6 cycles of DP and which resulted near CR.

DISCUSSION

Diarrhea is one of the most common side effects of chemotherapy and docetaxel is commonly associated with diarrhea. CID can significantly affect the quality of life and may result fatal outcome either directly or indirectly from suboptimal therapy. The pathogenesis of CID is unclear and the studies about CID have focused on irinotecan. It is believed that toxicity to rapidly dividing crypt cells of the gut leads destruction and/or augmentation of intestinal enzymes. This disturbs the balance between absorption and secretion, and alters the osmotic gap in the gut, thereby resulting increased secretion of fluids and electrolytes into the stool (4, 7). Recently, it has been suggested that alterations to intestinal tight junctions play a pivotal role in the pathogenesis of CID (8).

Loperamide is an antidiarrheal agent with many actions of mechanisms: antisecretory, antiperistaltic effect inhibiting the calcium-binding protein calmodulin and direct effect on the gastrointestinal wall by interacting locally with neuronal mechanisms. Thereby, loperamide prolongs transit time, increases viscosity and bulk density, and reduces fecal volume and loss of fluids and electrolytes (9, 10).

In treatment of CID, several guidelines exist and loperamide plays a main role (1-4). But the prophylaxis of CID is not well established. Some guidelines recommend octreotide, a somatostatin analogue, for the prevention and the treatment of refractory CID (1, 2, 11). But octreotide is not easy to use due to the cost and the method of administration (injection).

In this patient, fasting and aggressive hydration with electrolyte supplements were started and loperamide was given for the management of CID. However severe diarrhea persisted more than 10 days. Despite the severe diarrhea, the tumor response was excellent, thus DP chemotherapy was continued with the prophylactic approach. Oral loperamide with regimen of 2 mg every 8 hr successfully prevented docetaxel induced diarrhea. Loperamide is easy to administer and cost effective. The

![Fig. 1. Contrast enhanced computed tomography scan of the chest. (A) Lung cancer in the medial aspect of right lower lobe (arrow), prior to chemotherapy. (B) Much decrease in size of the lung cancer after 2 cycles of docetaxel-cisplatin chemotherapy.](http://jkms.org)
role of loperamide in the prophylaxis of CID requires further studies including appropriate dosing and duration.

Rarely docetaxel induced colitis is reported and which is usually associated with acute abdominal pain, tenderness, febrile neutropenia, hemorrhagic diarrhea or oral stomatitis (12, 13). The mechanism of the colitis is proposed: initial mucosal damage; bacterial invasion; secretion of bacterial endotoxins; hemorrhage; ulceration; and ischemia, possible necrosis (14). In this case, he presented no suspicious symptoms or findings for colitis. But clinicians should consider colitis in a patient with docetaxel induced diarrhea because the outcome of colitis can be fatal and the use of loperamide in that case can worsen the outcome.

In conclusion, although further studies about the appropriate dosing and the schedule are required, we suggest oral loperamide as a prophylactic use in the CID: 2 mg every 8 hr from day 1 (starting before chemotherapy) to 5. Additionally, clinicians should concern the possibility of the docetaxel induced colitis when CID is suspicious.

REFERENCES

1. Richardson G, Dobish R. Chemotherapy induced diarrhea. J Oncol Pharm Pract 2007; 13: 181-98.
2. Stein A, Voigt W, Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol 2010; 2: 51-63.
3. Benson AB 3rd, Ajani JA, Catalano RB, Engelking C, Kornblau SM, Martenson JA Jr, McCallum R, Mitchell EP, O’Dorisio TM, Yokes EE, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 2004; 22: 2918-26.
4. Kornblau S, Benson AB, Catalano R, Champlin RE, Engelking C, Field M, Ippoliti C, Lazarus HM, Mitchell E, Rubin J, et al. Management of cancer treatment-related diarrhea: issues and therapeutic strategies. J Pain Symptom Manage 2000; 19: 118-29.
5. Eisenhauer EA, Vermorken JB. The toxoids: comparative clinical pharmacology and therapeutic potential. Drugs 1998; 55: 5-30.
6. DailyMed. TAXOTERE (docetaxel) injection, solution, concentrate [sanofi-aventis U.S. LLC]. Available at http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=82731db6-92fc-483b-9d73-9b28ed79b104 [accessed on 3 January 2014].
7. Saltz LB. Understanding and managing chemotherapy-induced diarrhea. J Support Oncol 2003; 1: 35–46.
8. Wardill HR, Bowen IM, Gibson RJ. Chemotherapy-induced gut toxicity: are alterations to intestinal tight junctions pivotal? Cancer Chemother Pharmacol 2012; 70: 627-35.
9. Ericsson CD, Johnson PC. Safety and efficacy of loperamide. Am J Med 1990; 88: 105-14S.
10. Kirby MG, Dukes GE, Heizer WD, Bryson JC, Powell JR. Effect of metoclopramide, bethanechol, and loperamide on gastric residence time, gastric emptying, and mouth-to-cecum transit time. Pharmacotherapy 1989; 9: 226-31.
11. Anthony L. New strategies for the prevention and reduction of cancer treatment-induced diarrhea. Semin Oncol Nurs 2003; 19: 17-21.
12. Carrion AF, Hosein PJ, Cooper EM, Lopes G, Pelaez L, Rocha-Lima CM. Severe colitis associated with docetaxel use: a report of four cases. World J Gastrointest Oncol 2010; 2: 390-4.
13. Stemmler HJ, Kenngotte S, Diepolder H, Heinemann V. Gastrointestinal toxicity associated with weekly docetaxel treatment. Ann Oncol 2002; 13: 978-81.
14. Sezer O, Eucker J, Possinger K. Colitis associated with docetaxel-based chemotherapy. Lancet 2000; 355: 1823-4.